T-DXd

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy

Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib